Clinical Trials on Glycogen Storage Disease Type 2 in Netherlands
Total 2172 results
-
University Medical Center GroningenUltragenyx Pharmaceutical IncCompletedGlycogen Storage Disease Type IANetherlands
-
Ultragenyx Pharmaceutical IncCompletedGlycogen Storage Disease Type IANetherlands, United States
-
Ultragenyx Pharmaceutical IncActive, not recruitingGlycogen Storage Disease Type IA | Von Gierke's Disease (GSD Type Ia)Netherlands, United States, Canada, Spain
-
Genzyme, a Sanofi CompanyCompletedPompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2Netherlands
-
Ultragenyx Pharmaceutical IncActive, not recruitingGlycogen Storage Disease Type IAUnited States, Brazil, Canada, Denmark, Germany, Italy, Netherlands, Spain
-
Spark TherapeuticsCompletedLysosomal Storage Diseases | Glycogen Storage Disease Type 2 | Pompe Disease (Late-onset) | Pompe Disease | LOPD | Acid Maltase DeficiencyUnited States, Italy, United Kingdom, Netherlands, France, Germany
-
Spark TherapeuticsActive, not recruitingLysosomal Storage Diseases | Glycogen Storage Disease Type II | Glycogen Storage Disease Type 2 | Pompe Disease (Late-onset) | Pompe Disease | LOPD | Acid Maltase DeficiencyUnited States, Canada, Netherlands, France, Denmark, Germany, Italy, United Kingdom
-
Genzyme, a Sanofi CompanyCompletedGlycogenesis 2 Acid Maltase Deficiency | Pompe Disease (Late-Onset) | Glycogen Storage Disease Type II (GSD II)United States, Netherlands, United Kingdom, Germany
-
University Medical Center GroningenUniversity of Oxford; University of the Faroe Islands; Stichting Stofwisselkracht and other collaboratorsCompleted
-
Genzyme, a Sanofi CompanyCompletedPompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2United States, France, Netherlands
-
Ultragenyx Pharmaceutical IncTerminatedGlycogen Storage Disease Type IIIUnited States, Netherlands
-
Genzyme, a Sanofi CompanyCompletedPompe Disease | Glycogen Storage Disease Type II (GSD II) | Acid Maltase DeficiencyUnited States, Belgium, Denmark, France, Germany, Netherlands, United Kingdom
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II Pompe DiseaseUnited States, Belgium, Denmark, France, Germany, Netherlands, United Kingdom
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type IIUnited States, France, Netherlands
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II (GSD-II) | Pompe Disease (Late-Onset) | Glycogenesis Type II | Acid Maltase Deficiency (AMD)United States, France, Canada, Netherlands, Australia
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II;Pompe's DiseaseCzechia, Taiwan, Belgium, Germany, Korea, Republic of, United States, Argentina, Australia, Austria, Brazil, Canada, Denmark, France, Hungary, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Russian Federation, Spain, Switzerland, Turk... and more
-
SanofiRecruitingGlycogen Storage Disease Type IIBelgium, United States, Italy, Spain, Taiwan, United Kingdom, Netherlands, France, Germany
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type IIUnited States, France, Germany, Israel, Italy, Netherlands, Taiwan
-
SanofiRecruitingGlycogen Storage Disease Type IIBelgium, United States, China, Germany, Italy, Netherlands, Spain, Taiwan, United Kingdom
-
Amicus TherapeuticsActive, not recruitingPompe DiseaseUnited States, Netherlands, United Kingdom, Australia, Germany, New Zealand
-
BioMarin PharmaceuticalTerminatedLate-onset Pompe DiseaseUnited States, United Kingdom, Germany, France, Italy, Portugal, Belgium, Netherlands
-
Amicus TherapeuticsActive, not recruitingPompe Disease (Late-onset)United States, Germany, Taiwan, Belgium, Australia, Slovenia, Spain, Netherlands, Hungary, Japan, Austria, United Kingdom, France, Argentina, Canada, Sweden, Denmark, New Zealand, Greece, Korea, Republic of, Bosnia and Herzegovina, Ita... and more
-
Amicus TherapeuticsCompletedPompe Disease (Late-onset)United States, Australia, Korea, Republic of, Japan, Taiwan, Belgium, Slovenia, New Zealand, United Kingdom, France, Argentina, Canada, Spain, Bosnia and Herzegovina, Germany, Sweden, Hungary, Austria, Bulgaria, Denmark, Greece, I... and more
-
Genzyme, a Sanofi CompanyRecruitingGlycogen Storage Disease Type II | Pompe DiseaseHungary, Croatia, Serbia, United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Denmark, France, Germany, Greece, Hong Kong, India, Indonesia, Israel, Italy, Japan, Jordan, Korea, Republic of, Kuwait and more
-
Vitaflo International, LtdUniversity College London Hospitals; University Medical Center Groningen; University... and other collaboratorsCompletedGlycogen Storage DiseaseUnited States, United Kingdom, France, Netherlands
-
Maastricht University Medical CenterUnknownType 2 Diabetes MellitusNetherlands
-
Ultragenyx Pharmaceutical IncCompletedGSD1Netherlands, United States, Canada, Spain
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
Hoffmann-La RocheCompleted
-
UMC UtrechtCompletedShared Decision Making Between Patients and GPs in the Treatment of Type 2 Diabetes in Primary Care.Type 2 Diabetes MellitusNetherlands
-
Leiden University Medical CenterAndaluz Health ServiceCompletedDiabetes Mellitus | Health Behavior | Self Efficacy | Type2 Diabetes Mellitus | Type1 Diabetes MellitusNetherlands, Spain
-
Maastricht University Medical CenterCompleted
-
Maastricht University Medical CenterNovo Nordisk A/SCompletedType 2 DiabetesNetherlands
-
University Medical Center GroningenBoehringer IngelheimEnrolling by invitationDiabetes Mellitus, Type 2 | Diabetes Mellitus | Diabetes | Diabetes Complications | Chronic Kidney Diseases | Albuminuria | CKD | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | CKD Stage 4 | CKD Stage 3 | Chronic Kidney Disease Due to Type 2 Diabetes Mellitus | Diabetes Mellitus Type 2 With ProteinuriaNetherlands
-
Radboud University Medical CenterNot yet recruitingDiabetes Mellitus Type 2 in ObeseNetherlands
-
M.H.H. KramerActive, not recruitingType2 DiabetesNetherlands
-
Maastricht UniversityZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedType 2 Diabetes MellitusNetherlands
-
Maastricht University Medical CenterUnilever R&DCompletedFasting | Fatty Liver, Nonalcoholic | Glycogen Depletion | Meal TimeNetherlands
-
Radboud University Medical CenterDutch Diabetes Research FoundationCompletedEffects of Atazanavir Treatment on Type 2 Diabetes Mellitus Related Endothelial Dysfunction (DM2ATV)Type 2 Diabetes Mellitus Related Endothelial DysfunctionNetherlands
-
AstraZenecaEli Lilly and CompanyCompletedType 2 Diabetes MellitusFinland, Netherlands, Sweden
-
Maastricht University Medical CenterEuropean Foundation for the Study of Diabetes; Netherlands Organisation for...Completed
-
Maastricht University Medical CenterAlpro FoundationCompletedObesity, Insulin Sensitivity, Type 2 Diabetes MellitusNetherlands
-
Amsterdam UMC, location VUmcEU FP7: SAFEGUARD consortiumCompleted
-
TNORecruiting
-
Amsterdam UMC, location VUmcCompletedType 2 Diabetes MellitusNetherlands
-
Academisch Ziekenhuis MaastrichtEuropean Foundation for the Study of DiabetesCompletedDiabetes Mellitus | Physical Activity | Sedentary Lifestyle | Type2 Diabetes | Aortic Stiffness | Arterial Stiffness | Physical Exercise | Pulse Wave Velocity | Light Intensity Physical Activity | Artery DiseaseNetherlands
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Recruiting
-
Ionis Pharmaceuticals, Inc.CompletedType 2 Diabetes MellitusNetherlands
-
Maastricht University Medical CenterTop Institute Food and NutritionCompletedType 2 DiabetesNetherlands
-
Ionis Pharmaceuticals, Inc.Completed